NATURALSHRIMP Business Summary

NaturalShrimp Inc. (SHMP) is a biotechnology aquaculture company currently transitioning from a land-based shrimp producer to a technology commercialization and water treatment firm following a 2025 court-ordered receivership and subsequent asset liquidation. Historically focused on generating revenue through the sale of gourmet-grade Pacific White shrimp produced via proprietary Recirculating Aquaculture Systems (RAS), the company pivoted in 2026 under a strategic agreement with Hydrenesis, Inc. This shift involves the acquisition of a perpetual, exclusive license for advanced aquaculture and water treatment technologies, moving the business model toward IP licensing and specialized water solutions. Despite legally changing its name to BlueFuture Aquatics, Inc. in mid-2026, the company continues to trade as SHMP on the OTC Expert Market. It operates as a distressed micro-cap entity within a competitive landscape that includes land-based aquaculture peers such as Salmon Evolution, Proximar Seafood, and The Kingfish Company, though it currently lags behind these competitors in operational scale and financial stability. As of July 2026, the company’s leadership has been entirely restructured following the March 2026 resignations of the long-standing executive team, including former CEO Gerald Easterling, CFO Bill Delgado, and CTO Tom Untermyer. David Antelo currently serves as the Chief Executive Officer and sole director, spearheading the corporate reorganization and the integration of Hydrenesis-sourced intellectual property. Antelo’s leadership is defined by a mandate to simplify the company's capital structure and resolve approximately $9 million in remaining net liabilities. Key stakeholders now include Hydrenesis, Inc., which holds significant economic interest through Series P-2 preferred stock, and secured lenders such as Streeterville Capital, who previously acquired the company’s legacy fixed assets. The board is expected to expand as the company emerges from its liquidation phase and attempts to commercialize its newly licensed technology portfolio.